i&i Biotech Fund will invest up to EUR 340 000 into Czech startup Sophomer s.r.o.

The funding will be used for further development. Sophomer s.r.o. specializes in the development and production of synthetic polymers for in vitro diagnostics.

PRAGUE, ČESKO, March 29, 2023/EINPresswire.com/ -- Czech academic startup Sophomer s.r.o. has announced an investment of up to EUR 340 000 from i&i Biotech Fund. The funding will be used for further technology development, team expansion and new laboratory space. Sophomer s.r.o. was established at the end of 2022 as a result of a collaboration between the Institute of Macromolecular Chemistry CAS, the company Elisa Development, and the bio-innovation center i&i Prague. The establishment of Sophomer represents another unique example of successful technology transfer.

Sophomer s.r.o. specializes in the development and production of synthetic polymers for in vitro diagnostics. The first product to be launched in the upcoming months is SophoMer F10. This polymer could fully replace the widely used bovine serum albumin (BSA) in common immunological assays. BSA blocks unwanted signals during testing, which in turn increases the measurement accuracy.

Martin Burkhard, managing director of Sophomer s.r.o., describes the key advantages of the new polymer: “Because the production of our fully synthetic polymer requires no animal-derived constituents, we eliminated the problem of pathogen occurrence and the associated need to obtain veterinary certificates. It also means we’re able to produce individual lots in a standardized quality, which typically presents a significant challenge otherwise. Lastly, SophoMer F10 is at least five times more efficient than BSA.”

The company is currently collaborating with a leading European manufacturer on the development of diagnostic kits utilizing SophoMer F10 as the primary component. In addition, internal tests carried out by several important in vitro diagnostics manufacturers are nearing completion. If everything turns out well, nothing should prevent the world's largest manufacturers from using SophoMer F10 polymer in their diagnostic kits. Finally, Sophomer s.r.o. has also recently begun developing three additional polymers.

Tomáš Maršálek, partner at i&i Biotech Fund further explains the reasons for the investment. “We were particularly interested in this young Czech startup because of its dynamism. In record time its team managed to sign a licensing agreement, start operations, secure the first contract, and launch the first product. We have every faith in their science and in their ability to attract industry partners. We’re pleased to be a part of this promising project from square one,” says Tomáš Maršálek.

The ability to attract its first investor represents an important milestone in the history of the company, the creation of which is a model example of effective technology transfer. “Technology transfer is a long haul, but it’s an essential part of conveying research results into practice. Without it, many outstanding scientific discoveries would fall to succeed. Our task in this journey is to be a useful intermediary, helping cutting-edge technologies find applications on the market,” explains Jiří Moos from i&i Prague, which has been with the project since its inception.

Contact
Martin Kovalčík, kovalcik@inibio.eu, +420 777 472 863

About Sophomer s.r.o.
Sophomer s.r.o. is an academic startup founded by a group of people who come from both industry and academia. Their vision is to bring together two seemingly unrelated fields: immunochemistry and polymer chemistry to help anyone who uses immunoassays in their work. One of the startup's first and widely applicable products is SophoMer F10, a polymer that can replace the widely used bovine serum albumin, currently a component without which the development of immunological analytics is seemingly unimaginable. Read more here: www.sophomer.com.

About i&i Biotech Fund (i&i Bio)
i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund (see below). With over €47M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies. Read more here: www.inibio.eu.
​
About i&i Prague
i&i Prague focuses on the transfer of new technologies into practice. It was established at the Institute of Organic Chemistry and Biochemistry of the CAS and is dedicated to innovations in the field of drug development, diagnostics and medical devices originating from academic institutions. It supports the creation of spin-off companies and the sale of licenses. So far, the company has participated in the creation of or otherwise supported 15 spin-off companies from 5 countries, has an equity stake in 9 of them and has invested over 70 million crowns. Overall, the spin-offs in i&i Prague's portfolio have raised more than CZK 1.8 billion from other investors. In 2021, i&i Prague established the i&i Bio Investment Fund in cooperation with the European Investment Fund. For more information visit www.iniprague.com.

Martin Kovalčík
Biotech Investments s.r.o., VAT: CZ10885978
+420 777472863
email us here
Visit us on social media:
LinkedIn

SophoMer™ F10: How does it work?